Vertex Pharmaceuticals Incorporated (VRTX) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Vertex Pharmaceuticals Incorporated (VRTX) Profile & Business Summary
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Key Information
| Ticker | VRTX |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.vrtx.com |
Market Trend Overview for VRTX
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-08-17 (ET)
As of 2026-08-17, VRTX is starting to move higher. Over the longer term, the trend remains bullish.
VRTX last closed at 515.55. The price is about 1.0 ATR above its recent average price (504.95), and the market is currently in an early upward move. Price at 515.55 is holding above minor support near 469.60. If price continues higher, it may face minor resistance around 533.67. View Support & Resistance from Options
The trend is still positive, but signs of slowing momentum suggest growing two-sided risk.
Trend score: 80 out of 100. Overall alignment is strong. The market is currently in an early-stage uptrend. Trend signals are well aligned across timeframes, suggesting a stable and consistent trend.
A key downside risk boundary is near 447.03. If price falls below this area, the current structure would likely weaken further.
A systematic trend-activation signal was most recently triggered on 2026-08-11, reflecting a technical shift toward positive directional alignment.
[2026-08-13] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
As of 2026-08-11, price has extended significantly above its primary volume area, entering a liquidity-thin zone. While the uptrend remains intact, the risk of chasing strength has increased.
The model sees a credible bullish edge, with 65.7% upside probability, strong signal alignment, and reward/risk that remains meaningfully favorable.
Up probability is 65.7%, with predictability at 64% and signal agreement at 93%. Reversal risk is 13%, while reward/risk stands at 0.38. That suggests the directional case is supported by broad confirmation and still retains usable quality.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 18 trading days, with turnover-based decay. The sample period is 2026-07-23 to 2026-08-17. The current price is 515.55, 3.92% above the estimated average cost of 496.13. An estimated 71.4% of recent positioning is below the current price, while 28.2% is above it. The peak-density price is 479.00. The largest concentrated cost region is 482.10 to 487.90 and contains 18.2% of the estimated distribution. The current price is within the 515.30 to 515.70 cost region. The nearest region below the current price is 489.90 to 491.10. The nearest region above the current price is 524.90 to 526.90.
Short Interest & Covering Risk for VRTX
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 22%)
Structure Analysis
VRTX Short positioning looks normal. Current days to cover is 3.0 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 6/100, DTC percentile 43%) while price maintains a mild upward bias (20D return 7.3%) and liquidity softening modestly (volume -6%).
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Price action is compressing (range is tightening), which can make breaks more sensitive. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-07-31 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.